Pediatric and adult patients who have high-risk solid tumors with known positivity for one or more Tumor Antigen Associated (TAA) (WT1, PRAME and/or survivin) will be eligible. Patients will be enrolled in one of two groups: group A includes patients who have undergone an allogeneic HSCT as part of their prior therapy and group B includes patients who have undergone standard therapy which does not include an allogeneic HSCT. TAA CTL may be generated from donor lymphocytes (group A) obtained from either patient peripheral blood mononuclear cells (PBMC) or donor PBMC or host lymphocytes (group B).